Andrew Alexander joined Inotiv in 2020, adding his considerable experience in pharmacology and toxicology operations to provide broader expertise to Inotiv’s clients. He has over 25 years of preclinical toxicology experience serving pharmaceutical, biotech, medical device, and veterinary companies, as well as CROs and academic institutions. He established a reputation as a leader, working in roles of increasing responsibility for more than a decade, providing scientific expertise and study direction to clients. He then founded his own company, Scientific Business Advisors, which provided scientific and regulatory consulting services. He is a frequently published research scientist and a diplomate of the American Board of Toxicology.
He earned his DVM, PhD, MBA, and a postdoctoral fellowship in oncology and immunology from the University of Wisconsin, and completed a surgical internship at the School of Veterinary Medicine at the University of Illinois.